Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology

Immunology

Volumn 150, Issue 3, 2017, Pages 248-264

  Béziat, Vivien ^a   Hilton, Hugo G ^b   Norman, Paul J ^b   Traherne, James A ^c  

^a IMAGINE INSTITUTE   (France)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

expression; haplotypes; killer cell immunoglobulin like receptors; ligands; natural killer cell; polymorphism

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; PEPTIDE;

ALLELE; ALLOTYPE; BALANCING SELECTION; CYTOLOGY; DISEASE ASSOCIATION; DISEASES; EVOLUTION; GENE EXPRESSION; GENETIC VARIABILITY; GENETIC VARIATION; GENETICS; HAPLOTYPE; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; LIGAND BINDING; NATURAL KILLER CELL; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; ADAPTIVE IMMUNITY; ANIMAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PREGNANCY; REPRODUCTION;

ADAPTIVE IMMUNITY; ANIMALS; BIOLOGICAL EVOLUTION; FEMALE; GENOTYPE; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; PLACENTATION; POLYMORPHISM, GENETIC; PREGNANCY; RECEPTORS, KIR; T-LYMPHOCYTES;

EID: 85007198840     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12684     Document Type: Review

References (237)

1. Battistini L, Borsellino G, Sawicki G, Poccia F, Salvetti M, Ristori G et al. Phenotypic and cytokine analysis of human peripheral blood γδ T cells expressing NK cell receptors. J Immunol 1997; 159:3723–30.
2. Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol 2001; 166:3933–41.
3. Patterson S, Chaidos A, Neville DC, Poggi A, Butters TD, Roberts IA et al. Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors. J Immunol 2008; 181:3268–76.
4. + T cells specific for cytomegalovirus. J Immunol 2009; 182:4175–82.
5. + T cells. J Immunol 2004; 173:7223–9.
6. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225–74.
7. Bjorkstrom NK, Beziat V, Cichocki F, Liu LL, Levine J, Larsson S et al. CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. Blood 2012; 120:3455–65.
8. + T lymphocytes. J Immunol 2008; 180:2767–71.
9. Barclay AN, Hatherley D. The counterbalance theory for evolution and function of paired receptors. Immunity 2008; 29:675–8.
10. Liu J, Xiao Z, Ko HL, Shen M, Ren EC. Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci USA 2014; 111:2662–7.
11. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med 2009; 206:2557–72.
12. Karre K. Natural killer cell recognition of missing self. Nat Immunol 2008; 9:477–80.
13. Yokoyama WM, Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 2006; 214:143–54.
14. Orr MT, Lanier LL. Natural killer cell education and tolerance. Cell 2010; 142:847–56.
15. Trowsdale J, Jones DC, Barrow AD, Traherne JA. Surveillance of cell and tissue perturbation by receptors in the LRC. Immunol Rev 2015; 267:117–36.
16. Benson DM Jr, Caligiuri MA. Killer immunoglobulin-like receptors and tumor immunity. Cancer Immunol Res 2014; 2:99–104.
17. Parham P, Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013; 13:133–44.
18. Jiang W, Johnson C, Jayaraman J, Simecek N, Noble J, Moffatt MF et al. Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. Genome Res 2012; 22:1845–54.
19. Norman PJ, Cook MA, Carey BS, Carrington CV, Verity DH, Hameed K et al. SNP haplotypes and allele frequencies show evidence for disruptive and balancing selection in the human leukocyte receptor complex. Immunogenetics 2004; 56:225–37.
20. Martin MP, Bashirova A, Traherne J, Trowsdale J, Carrington M. Cutting edge: expansion of the KIR locus by unequal crossing over. J Immunol 2003; 171:2192–5.
21. Traherne JA, Martin M, Ward R, Ohashi M, Pellett F, Gladman D et al. Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum Mol Genet 2010; 19:737–51.
22. Norman PJ, Abi-Rached L, Gendzekhadze K, Hammond JA, Moesta AK, Sharma D et al. Meiotic recombination generates rich diversity in NK cell receptor genes, alleles, and haplotypes. Genome Res 2009; 19:757–69.
23. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7:753–63.
24. Gumperz JE, Valiante NM, Parham P, Lanier LL, Tyan D. Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibililty complex haplotype. J Exp Med 1996; 183:1817–27.
25. Pando MJ, Gardiner CM, Gleimer M, McQueen KL, Parham P. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 2003; 171:6640–9.
26. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D et al. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol 2002; 168:2307–15.
27. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429–34.
28. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169:2818–22.
29. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097–100.
30. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CW, Carrington M, Trowsdale J et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200:957–65.
31. VandenBussche CJ, Dakshanamurthy S, Posch PE, Hurley CK. A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain. J Immunol 2006; 177:5347–57.
32. Goodridge JP, Lathbury LJ, Steiner NK, Shulse CN, Pullikotil P, Seidah NG et al. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol 2007; 37:199–211.
33. Mulrooney TJ, Hou L, Steiner NK, Chen M, Belle I, Ng J et al. Promoter variants of KIR2DL5 add to diversity and may impact gene expression. Immunogenetics 2008; 60:287–94.
34. Hilton HG, Norman PJ, Nemat-Gorgani N, Goyos A, Hollenbach JA, Henn BM et al. Loss and gain of natural killer cell receptor function in an African Hunter–Gatherer population. PLoS Genet 2015; 11:e1005439.
35. Vivian JP, Duncan RC, Berry R, O'Connor GM, Reid HH, Beddoe T et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011; 479:401–5.
36. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol 1997; 158:4026–8.
37. Beziat V, Traherne JA, Liu LL, Jayaraman J, Enqvist M, Larsson S et al. Influence of KIR gene copy number on natural killer cell education. Blood 2013; 121:4703–7.
38. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006; 203:633–45.
39. Boudreau JE, Mulrooney TJ, Le Luduec JB, Barker E, Hsu KC. KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV. J Immunol 2016; 196:3398–410.
40. Hilton HG, Guethlein LA, Goyos A, Nemat-Gorgani N, Bushnell DA, Norman PJ et al. Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes. J Immunol 2015; 195:3160–70.
41. Saunders PM, Pymm P, Pietra G, Hughes VA, Hitchen C, O'Connor GM et al. Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition. J Exp Med 2016; 213:791–807.
42. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007; 178:33–7.
43. Frazier WR, Steiner N, Hou L, Dakshanamurthy S, Hurley CK. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J Immunol 2013; 190:6198–208.
44. Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 2006; 7:277–300.
45. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Guethlein LA, Hilton HG, Pando MJ et al. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet 2013; 9:e1003938.
46. Nemat-Gorgani N, Edinur HA, Hollenbach JA, Traherne JA, Dunn PP, Chambers GK et al. KIR diversity in Māori and Polynesians: populations in which HLA-B is not a significant KIR ligand. Immunogenetics 2014; 66:597–611.
47. Guethlein LA, Older Aguilar AM, Abi-Rached L, Parham P. Evolution of killer cell Ig-like receptor (KIR) genes: definition of an orang-utan KIR haplotype reveals expansion of lineage III KIR associated with the emergence of MHC-C. J Immunol 2007; 179:491–504.
48. Khakoo SI, Rajalingam R, Shum BP, Weidenbach K, Flodin L, Muir DG et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 2000; 12:687–98.
49. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics 2001; 52:195–205.
50. Toneva M, Lepage V, Lafay G, Dulphy N, Busson M, Lester S et al. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens 2001; 57:358–62.
51. Hollenbach JA, Nocedal I, Ladner MB, Single RM, Trachtenberg EA. Killer cell immunoglobulin-like receptor (KIR) gene content variation in the HGDP-CEPH populations Immunogenetics 2012; 64:719–37.
52. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997; 7:739–51.
53. Hedrick PW, Thomson G. Evidence for balancing selection at HLA. Genetics 1983; 104:449–56.
54. Greenberg JH, Turner CG, Zegura SL, Campbell L, Fox JA, Laughlin WS et al. The settlement of the Americas: a comparison of the linguistic, dental, and genetic evidence [and comments and reply]. Curr Anthropol 1986; 27:477–97.
55. Gendzekhadze K, Norman PJ, Abi-Rached L, Graef T, Moesta AK, Layrisse Z et al. Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc Natl Acad Sci USA 2009; 106:18692–7.
56. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, Silva AL et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 2015; 43:D784–8.
57. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872–4.
58. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733–40.
59. Hiby SE, Apps R, Chazara O, Farrell LE, Magnus P, Trogstad L et al. Maternal KIR in combination with paternal HLA-C2 regulate human birth weight. J Immunol 2014; 192:5069–73.
60. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015; 43:D423–31.
61. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, Rowley D et al. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet 2007; 39:1092–9.
62. O'Connor GM, Vivian JP, Widjaja JM, Bridgeman JS, Gostick E, Lafont BA et al. Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. J Immunol 2014; 192:2875–84.
63. Fadda L, O'Connor GM, Kumar S, Piechocka-Trocha A, Gardiner CM, Carrington M et al. Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J Virol 2011; 85:5970–4.
64. O'Connor GM, Vivian JP, Gostick E, Pymm P, Lafont BA, Price DA et al. Peptide-dependent recognition of HLA-B*57:01 by KIR3DS1. J Virol 2015; 89:5213–21.
65. O'Connor GM, Yamada E, Rampersaud A, Thomas R, Carrington M, McVicar DW. Analysis of binding of KIR3DS1*014 to HLA suggests distinct evolutionary history of KIR3DS1. J Immunol 2011; 187:2162–71.
66. Abi-Rached L, Moesta AK, Rajalingam R, Guethlein LA, Parham P. Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cells. PLoS Genet 2010; 6:e1001192.
67. Abi-Rached L, Parham P. Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J Exp Med 2005; 201:1319–32.
68. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Marin WM, Norberg SJ, Ashouri E et al. Defining KIR and HLA class i genotypes at highest resolution via high-throughput sequencing. Am J Hum Genet 2016; 99:375–91.
69. Single RM, Martin MP, Gao X, Meyer D, Yeager M, Kidd JR et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007; 39:1114–9.
70. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2001; 2:452–60.
71. Pelak K, Need AC, Fellay J, Shianna KV, Feng S, Urban TJ et al. Copy number variation of KIR genes influences HIV-1 control. PLoS Biol 2011; 9:e1001208.
72. O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 2007; 178:235–41.
73. Song S, Miranda CJ, Braun L, Meyer K, Frakes AE, Ferraiuolo L et al. Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nat Med 2016; 22:397–403.
74. Ahn RS, Moslehi H, Martin MP, Abad-Santos M, Bowcock AM, Carrington M et al. Inhibitory KIR3DL1 alleles are associated with psoriasis. Br J Dermatol 2015; 174:449–51.
75. Augusto DG, O'Connor GM, Lobo-Alves SC, Bass S, Martin MP, Carrington M et al. Pemphigus is associated with KIR3DL2 expression levels and provides evidence that KIR3DL2 may bind HLA-A3 and A11 in vivo. Eur J Immunol 2015; 45:2052–60.
76. Nakimuli A, Chazara O, Hiby SE, Farrell L, Tukwasibwe S, Jayaraman J et al. A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia. Proc Natl Acad Sci USA 2015; 112:845–50.
77. Vukcevic D, Traherne JA, Naess S, Ellinghaus E, Kamatani Y, Dilthey A et al. Imputation of KIR types from SNP variation data. Am J Hum Genet 2015; 97:593–607.
78. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14:661–73.
79. Kulkarni S, Martin MP, Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008; 20:343–52.
80. Martin MP, Carrington M. Immunogenetics of HIV disease. Immunol Rev 2013; 254:245–64.
81. Chen H, Hayashi G, Lai OY, Dilthey A, Kuebler PJ, Wong TV et al. Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. PLoS Genet 2012; 8:e1002514.
82. Garrido-Rodriguez D, Avila-Rios S, Garcia-Morales C, Valenzuela-Ponce H, Ormsby C, Reyes-Gopar H et al. Killer cell immunoglobulin-like receptor and human leukocyte antigen gene profiles in a cohort of HIV-infected Mexican Mestizos. Immunogenetics 2016; 68:703–17.
83. Robinson J, Halliwell JA, Marsh SG. IMGT/HLA and the immuno polymorphism database. Methods Mol Biol 2014; 1184:109–21.
84. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, Canese K et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2012; 40:D13–25.
85. Horton R, Coggill P, Miretti MM, Sambrook JG, Traherne JA, Ward R et al. The LRC haplotype project: a resource for killer immunoglobulin-like receptor-linked association studies. Tissue Antigens 2006; 68:450–2.
86. Apps R, Del Prete GQ, Chatterjee P, Lara A, Brumme ZL, Brockman MA et al. HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host Microbe 2016; 19:686–95.
87. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10:661–71.
88. Garcia-Beltran WF, Holzemer A, Martrus G, Chung AW, Pacheco Y, Simoneau CR et al. Open conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1. Nat Immunol 2016; 17:1067–74.
89. Burian A, Wang KL, Finton KA, Lee N, Ishitani A, Strong RK et al. HLA-F and MHC-I Open Conformers Bind Natural Killer Cell Ig-Like Receptor KIR3DS1. PLoS ONE 2016; 11:e0163297.
90. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204:3027–36.
91. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R et al. Influence of HLA-C expression level on HIV control. Science 2013; 340:87–91.
92. Thomas R, Apps R, Qi Y, Gao X, Male V, O'HUigin C et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290–4.
93. Brackenridge S, Evans EJ, Toebes M, Goonetilleke N, Liu MK, di Gleria K et al. An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol 2011; 85:5415–22.
94. + T cells and NK cells. AIDS 2009; 23:189–93.
95. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011; 476:96–100.
96. Jiang W, Johnson C, Simecek N, López-Álvarez MR, Di D, Trowsdale J. qKAT: a high-throughput qPCR method for KIR gene copy number and haplotype determination. Genome Med 2016; 8:99.
97. Vendelbosch S, de Boer M, Gouw RA, Ho CK, Geissler J, Swelsen WT et al. Extensive variation in gene copy number at the killer immunoglobulin-like receptor locus in humans. PLoS ONE 2013; 8:e67619.
98. Roberts CH, Jiang W, Jayaraman J, Trowsdale J, Holland MJ, Traherne JA. Killer-cell Immunoglobulin-like Receptor gene linkage and copy number variation analysis by droplet digital PCR. Genome Med 2014; 6:20.
99. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000; 405:537–43.
100. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998; 161:571–7.
101. Winter CC, Long EO. Binding of soluble KIR-Fc fusion proteins to HLA class I. Methods Mol Biol 2000; 121:239–50.
102. Hilton HG, Moesta AK, Guethlein LA, Blokhuis J, Parham P, Norman PJ. The production of KIR-Fc fusion proteins and their use in a multiplex HLA class I binding assay. J Immunol Methods 2015; 425:79–87.
103. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180:3969–79.
104. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA 1993; 90:12000–4.
105. Moretta A, Vitale M, Bottino C, Orengo AM, Morelli L, Augugliaro R et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993; 178:597–604.
106. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci USA 2010; 107:10160–5.
107. Frazier WR, Steiner N, Hou L, Dakshanamurthy S, Hurley CK. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand. J Immunol 2013; 190:6198–208.
108. Bari R, Thapa R, Bao J, Li Y, Zheng J, Leung W et al. KIR2DL2/2DL3-E(35) alleles are functionally stronger than -Q(35) alleles. Sci Rep 2016; 6:23689.
109. Moesta AK, Abi-Rached L, Norman PJ, Parham P. Chimpanzees use more varied receptors and ligands than humans for inhibitory killer cell Ig-like receptor recognition of the MHC-C1 and MHC-C2 epitopes. J Immunol 2009; 182:3628–37.
110. Hilton HG, Vago L, Older Aguilar AM, Moesta AK, Graef T, Abi-Rached L et al. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J Immunol 2012; 189:1418–30.
111. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008; 112:2369–80.
112. Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N et al. Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 2009; 114:5182–90.
113. Oszmiana A, Williamson DJ, Cordoba SP, Morgan DJ, Kennedy PR, Stacey K et al. The size of activating and inhibitory killer Ig-like receptor nanoclusters is controlled by the transmembrane sequence and affects signaling. Cell Rep 2016; 15:1957–72.
114. Gumperz JE, Barber LD, Valiante NM, Percival L, Phillips JH, Lanier LL et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol 1997; 158:5237–41.
115. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995; 181:1133–44.
116. + HLA-B with KIR3DL1. J Immunol 2008; 181:6293–300.
117. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995; 267:1016–8.
118. Peruzzi M, Wagtmann N, Long EO. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J Exp Med 1996; 184:1585–90.
119. Cella M, Longo A, Ferrara GB, Strominger JL, Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J Exp Med 1994; 180:1235–42.
120. Kuranov AB, Kotter I, Henes JC, Abisheva ST, Steiert I, Riewerts F et al. Behçet's disease in HLA-B*51 negative Germans and Turks shows association with HLA-Bw4-80I. Arthritis Res Ther 2014; 16:R116.
121. Marra J, Greene J, Hwang J, Du J, Damon L, Martin T et al. KIR and HLA genotypes predictive of low-affinity interactions are associated with lower relapse in autologous hematopoietic cell transplantation for acute myeloid leukemia. J Immunol 2015; 194:4222–30.
122. Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 2014; 258:45–63.
123. Mulrooney TJ, Zhang AC, Goldgur Y, Boudreau JE, Hsu KC. KIR3DS1-specific D0 domain polymorphisms disrupt KIR3DL1 surface expression and HLA binding. J Immunol 2015; 195:1242–50.
124. Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010; 120:4102–10.
125. Ivarsson MA, Michaelsson J, Fauriat C. Activating killer cell Ig-like receptors in health and disease. Front Immunol 2014; 5:184.
126. Moesta AK, Graef T, Abi-Rached L, Older Aguilar AM, Guethlein LA, Parham P. Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. J Immunol 2010; 185:4233–7.
127. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A et al. Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005; 102:13224–9.
128. Katz G, Markel G, Mizrahi S, Arnon TI, Mandelboim O. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4. J Immunol 2001; 166:7260–7.
129. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002; 296:1323–6.
130. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci USA 2002; 99:8826–31.
131. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012; 481:394–8.
132. Robinson J, Halliwell JA, McWilliam H, Lopez R, Marsh SG. IPD – the immuno polymorphism database. Nucleic Acids Res 2013; 41:D1234–40.
133. Nowak I, Ploski R, Barcz E, Dziunycz P, Kaminski P, Kostrzewa G et al. KIR2DS5 in the presence of HLA-C C2 protects against endometriosis. Immunogenetics 2015; 67:203–9.
134. Cassidy SA, Cheent KS, Khakoo SI. Effects of peptide on NK cell-mediated MHC I recognition. Front Immunol 2014; 5:133.
135. Das J, Khakoo SI. NK cells: tuned by peptide? Immunol Rev 2015; 267:214–27.
136. + natural killer cells: data from an observational cohort in South Africa. PLoS Med 2015; 12:e1001900; discussion e1001900.
137. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999; 189:1093–100.
138. Trompeter HI, Gomez-Lozano N, Santourlidis S, Eisermann B, Wernet P, Vilches C et al. Three structurally and functionally divergent kinds of promoters regulate expression of clonally distributed killer cell Ig-like receptors (KIR), of KIR2DL4, and of KIR3DL3. J Immunol 2005; 174:4135–43.
139. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P et al. Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 2002; 169:4253–61.
140. Chan HW, Kurago ZB, Stewart CA, Wilson MJ, Martin MP, Mace BE et al. DNA methylation maintains allele-specific KIR gene expression in human natural killer cells. J Exp Med 2003; 197:245–55.
141. Li G, Yu M, Weyand CM, Goronzy JJ. Epigenetic regulation of killer immunoglobulin-like receptor expression in T cells. Blood 2009; 114:3422–30.
142. Li H, Pascal V, Martin MP, Carrington M, Anderson SK. Genetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression. PLoS Genet 2008; 4:e1000254.
143. Davies GE, Locke SM, Wright PW, Li H, Hanson RJ, Miller JS et al. Identification of bidirectional promoters in the human KIR genes. Genes Immun 2007; 8:245–53.
144. Cichocki F, Lenvik T, Sharma N, Yun G, Anderson SK, Miller JS. Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-like RNA in human NK cells. J Immunol 2010; 185:2009–12.
145. Freund J, May RM, Yang E, Li H, McCullen M, Zhang B et al. Activating receptor signals drive receptor diversity in developing natural killer cells. PLoS Biol 2016; 14:e1002526.
146. Wright PW, Li H, Huehn A, O'Connor GM, Cooley S, Miller JS et al. Characterization of a weakly expressed KIR2DL1 variant reveals a novel upstream promoter that controls KIR expression. Genes Immun 2014; 15:440–8.
147. Vilches C, Gardiner CM, Parham P. Gene structure and promoter variation of expressed and nonexpressed variants of the KIR2DL5 gene. J Immunol 2000; 165:6416–21.
148. Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853–64.
149. dim human NK-cell subsets. Blood 2010; 115:274–81.
150. Beziat V, Descours B, Parizot C, Debre P, Vieillard V. NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS ONE 2010; 5:e11966.
151. + T cells. J Immunol 2009; 182:92–101.
152. van Bergen J, Thompson A, van der Slik A, Ottenhoff TH, Gussekloo J, Koning F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol 2004; 173:6719–26.
153. Warren HS, Rana PM, Rieger DT, Hewitt KA, Dahlstrom JE, Kent AL. CD8 T cells expressing killer Ig-like receptors and NKG2A are present in cord blood and express a more naive phenotype than their counterparts in adult blood. J Leukoc Biol 2006; 79:1252–9.
154. Le Garff-Tavernier M, Beziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E et al. Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 2010; 9:527–35.
155. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331–42.
156. Andersson S, Fauriat C, Malmberg JA, Ljunggren HG, Malmberg KJ. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009; 114:95–104.
157. Schonberg K, Sribar M, Enczmann J, Fischer JC, Uhrberg M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011; 117:98–107.
158. Schonberg K, Fischer JC, Kogler G, Uhrberg M. Neonatal NK-cell repertoires are functionally, but not structurally, biased toward recognition of self HLA class I. Blood 2011; 117:5152–6.
159. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004; 104:3664–71.
160. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013; 121:2678–88.
161. –/– umbilical cord blood. J Immunol 2014; 192:1471–9.
162. Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA et al. Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. Cell Rep 2016; 15:1088–99.
163. Muntasell A, Pupuleku A, Cisneros E, Vera A, Moraru M, Vilches C et al. Relationship of NKG2C copy number with the distribution of distinct cytomegalovirus-induced adaptive NK cell subsets. J Immunol 2016; 196:3818–27.
164. + NK cells in TAP-deficient patients. Front Immunol 2015; 6:507.
165. + NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol 2012; 42:447–57.
166. Petitdemange C, Becquart P, Wauquier N, Beziat V, Debre P, Leroy EM et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 2011; 7:e1002268.
167. Lindgren T, Ahlm C, Mohamed N, Evander M, Ljunggren HG, Bjorkstrom NK. Longitudinal analysis of the human T cell response during acute hantavirus infection. J Virol 2011; 85:10252–60.
168. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E et al. Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection. AIDS 2010; 24:27–34.
169. Bjorkstrom NK, Svensson A, Malmberg KJ, Eriksson K, Ljunggren HG. Characterization of natural killer cell phenotype and function during recurrent human HSV-2 infection. PLoS ONE 2011; 6:e27664.
170. Azzi T, Lunemann A, Murer A, Ueda S, Beziat V, Malmberg KJ et al. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 2014; 124:2533–43.
171. Wilkinson GW, Tomasec P, Stanton RJ, Armstrong M, Prod'homme V, Aicheler R et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol 2008; 41:206–12.
172. Fielding CA, Aicheler R, Stanton RJ, Wang EC, Han S, Seirafian S et al. Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation. PLoS Pathog 2014; 10:e1004058.
173. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Microbiol 2005; 3:59–69.
174. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000; 164:5019–22.
175. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000; 287:1031.
176. Khan N, Bruton R, Taylor GS, Cobbold M, Jones TR, Rickinson AB et al. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J Virol 2005; 79:2869–79.
177. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol J 2009; 6:4.
178. Hoglund P, Glas R, Ohlen C, Ljunggren HG, Karre K. Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med 1991; 174:327–34.
179. Bonorino P, Leroy V, Dufeu-Duchesne T, Tongiani-Dashan S, Sturm N, Pernollet M et al. Features and distribution of CD8 T cells with human leukocyte antigen class I-specific receptor expression in chronic hepatitis C. Hepatology 2007; 46:1375–86.
180. Snyder MR, Nakajima T, Leibson PJ, Weyand CM, Goronzy JJ. Stimulatory killer Ig-like receptors modulate T cell activation through DAP12-dependent and DAP12-independent mechanisms. J Immunol 2004; 173:3725–31.
181. Guerra N, Michel F, Gati A, Gaudin C, Mishal Z, Escudier B et al. Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. Blood 2002; 100:2874–81.
182. Henel G, Singh K, Cui D, Pryshchep S, Lee WW, Weyand CM et al. Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin-like receptors. Blood 2006; 107:4449–57.
183. + T cells. Nat Immunol 2001; 2:430–5.
184. + NK cells. J Immunol 2015; 194:2467–71.
185. Sharkey AM, Gardner L, Hiby S, Farrell L, Apps R, Masters L et al. Killer Ig-like receptor expression in uterine NK cells is biased toward recognition of HLA-C and alters with gestational age. J Immunol 2008; 181:39–46.
186. Ivarsson MA, Stiglund N, Marquardt N, Westgren M, Gidlof S, Bjorkstrom NK. Composition and dynamics of the uterine NK cell KIR repertoire in menstrual blood. Mucosal Immunol, 2016; doi: 10.1038/mi.2016.50.
187. Beziat V, Traherne J, Malmberg JA, Ivarsson MA, Bjorkstrom NK, Retiere C et al. Tracing dynamic expansion of human NK-cell subsets by high-resolution analysis of KIR repertoires and cellular differentiation. Eur J Immunol 2014; 44:2192–6.
188. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med 2013; 5:208ra145.
189. Bjorkstrom NK, Ljunggren HG, Michaelsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol 2016; 16:310–20.
190. van Unen V, Li N, Molendijk I, Temurhan M, Hollt T, van der Meulen-de Jong AE et al. Mass cytometry of the human mucosal immune system identifies tissue- and disease-associated immune subsets. Immunity 2016; 44:1227–39.
191. Strauss-Albee DM, Horowitz A, Parham P, Blish CA. Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol 2014; 193:4871–9.
192. Czaja K, Borer AS, Schmied L, Terszowski G, Stern M, Gonzalez A. A comprehensive analysis of the binding of anti-KIR antibodies to activating KIRs. Genes Immun 2014; 15:33–7.
193. De Miguel M, López-Botet M. Characterization of monoclonal antibodies specific for receptors of the KIR family. Inmunología 2002; 21:187–93.
194. Falco M, Romeo E, Marcenaro S, Martini S, Vitale M, Bottino C et al. Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining. J Immunol 2010; 185:433–41.
195. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995; 182:875–84.
196. Moretta A, Ciccone E, Tambussi G, Bottino C, Viale O, Pende D et al. Surface molecules involved in CD3-negative NK cell function. A novel molecule which regulates the activation of a subset of human NK cells. Int J Cancer Suppl 1989; 4:48–52.
197. + natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990; 171:695–714.
198. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M et al. The human leukocyte antigen (HLA)-C-specific “activatory” or “inhibitory” natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996; 183:645–50.
199. Ferrini S, Cambiaggi A, Meazza R, Sforzini S, Marciano S, Mingari MC et al. T cell clones expressing the natural killer cell-related p58 receptor molecule display heterogeneity in phenotypic properties and p58 function. Eur J Immunol 1994; 24:2294–8.
200. Estefania E, Flores R, Gomez-Lozano N, Aguilar H, Lopez-Botet M, Vilches C. Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets. J Immunol 2007; 178:4402–10.
201. David G, Morvan M, Gagne K, Kerdudou N, Willem C, Devys A et al. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies. Immunology 2009; 128:172–84.
202. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 1997; 186:1129–36.
203. Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med 1994; 180:537–43.
204. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001; 166:2992–3001.
205. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 2007; 178:647–51.
206. Trundley A, Frebel H, Jones D, Chang C, Trowsdale J. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur J Immunol 2007; 37:780–7.
207. Leong CC, Chapman TL, Bjorkman PJ, Formankova D, Mocarski ES, Phillips JH et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 1998; 187:1681–7.
208. Spaggiari GM, Contini P, Carosio R, Arvigo M, Ghio M, Oddone D et al. Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood 2002; 99:1706–14.
209. Zhang H, Zhou L, Zhu Z, Yang C. Recent progress in aptamer-based functional probes for bioanalysis and biomedicine. Chemistry 2016; 22:9886–900.
210. Rahim MM, Makrigiannis AP. Ly49 receptors: evolution, genetic diversity, and impact on immunity. Immunol Rev 2015; 267:137–47.
211. Moffett A, Colucci F. Co-evolution of NK receptors and HLA ligands in humans is driven by reproduction. Immunol Rev 2015; 267:283–97.
212. Belkin D, Torkar M, Chang C, Barten R, Tolaini M, Haude A et al. Killer cell Ig-like receptor and leukocyte Ig-like receptor transgenic mice exhibit tissue- and cell-specific transgene expression. J Immunol 2003; 171:3056–63.
213. Boudreau JE, Liu XR, Zhao Z, Zhang A, Shultz LD, Greiner DL et al. Cell-extrinsic MHC Class I molecule engagement augments human NK cell education programmed by cell-intrinsic MHC Class I. Immunity 2016; 45:280–91.
214. Kruse PH, Rosner C, Walter L. Characterization of rhesus macaque KIR genotypes and haplotypes. Immunogenetics 2010; 62:281–93.
215. Averdam A, Petersen B, Rosner C, Neff J, Roos C, Eberle M et al. A novel system of polymorphic and diverse NK cell receptors in primates. PLoS Genet 2009; 5:e1000688.
216. Guethlein LA, Norman PJ, Hilton HH, Parham P. Co-evolution of MHC class I and variable NK cell receptors in placental mammals. Immunol Rev 2015; 267:259–82.
217. Rosner C, Kruse PH, Hermes M, Otto N, Walter L. Rhesus macaque inhibitory and activating KIR3D interact with Mamu-A-encoded ligands. J Immunol 2011; 186:2156–63.
218. Moreland AJ, Guethlein LA, Reeves RK, Broman KW, Johnson RP, Parham P et al. Characterization of killer immunoglobulin-like receptor genetics and comprehensive genotyping by pyrosequencing in rhesus macaques. BMC Genom 2011; 12:295.
219. Bimber BN, Evans DT. The killer-cell immunoglobulin-like receptors of macaques. Immunol Rev 2015; 267:246–58.
220. Older Aguilar AM, Guethlein LA, Hermes M, Walter L, Parham P. Rhesus macaque KIR bind human MHC class I with broad specificity and recognize HLA-C more effectively than HLA-A and HLA-B. Immunogenetics 2011; 63:577–85.
221. Hermes M, Weil S, Groth A, Dressel R, Koch J, Walter L. Characterisation of mouse monoclonal antibodies against rhesus macaque killer immunoglobulin-like receptors KIR3D. Immunogenetics 2012; 64:845–8.
222. Hermes M, Albrecht C, Schrod A, Brameier M, Walter L. Expression patterns of killer cell immunoglobulin-like receptors (KIR) of NK-cell and T-cell subsets in Old World monkeys. PLoS ONE 2013; 8:e64936.
223. Albrecht C, Malzahn D, Brameier M, Hermes M, Ansari AA, Walter L. Progression to AIDS in SIV-infected rhesus macaques is associated with distinct KIR and MHC class I polymorphisms and NK Cell dysfunction. Front Immunol 2014; 5:600.
224. Walter L, Ansari AA. MHC and KIR polymorphisms in Rhesus Macaque SIV infection. Front Immunol 2015; 6:540.
225. Zambello R, Teramo A, Barila G, Gattazzo C, Semenzato G. Activating KIRs in chronic lymphoproliferative disorder of NK cells: protection from viruses and disease induction? Front Immunol 2014; 5:72.
226. Zambello R, Trentin L, Ciccone E, Bulian P, Agostini C, Moretta A et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood 1993; 81:2381–5.
227. + T-cell large granular lymphocytosis. Hum Immunol 2011; 72:226–8.
228. Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW. T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules. Am J Clin Pathol 2005; 124:937–46.
229. Thonnart N, Caudron A, Legaz I, Bagot M, Bensussan A, Marie-Cardine A. KIR3DL2 is a coinhibitory receptor on Sezary syndrome malignant T cells that promotes resistance to activation-induced cell death. Blood 2014; 124:3330–2.
230. Battistella M, Janin A, Jean-Louis F, Collomb C, Leboeuf C, Sicard H et al. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 2016; 175:325–33.
231. Ruggeri L, Mancusi A, Urbani E, Velardi A. Identifying NK alloreactive donors for haploidentical hematopoietic stem cell transplantation. Methods Mol Biol 2016; 1393:141–5.
232. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012; 367:805–16.
233. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SG et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 2014; 192:4592–600.
234. Guillerey C, Smyth MJ. NK cells and cancer immunoediting. Curr Top Microbiol Immunol 2016; 395:115–45.
235. Liu LL, Pfefferle A, Yi Sheng VO, Bjorklund AT, Beziat V, Goodridge JP et al. Harnessing adaptive natural killer cells in cancer immunotherapy. Mol Oncol 2015; 9:1904–17.
236. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2016; 16:7–19.
237. Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014; 123:678–86.